Fibrinogen receptor antagonists induce conformational changes of the human platelet glycoprotein IIb

被引:6
作者
Seyfarth, HJ
Koksch, M
机构
[1] Univ Leipzig, Dept Pneumol, D-04103 Leipzig, Germany
[2] Univ Leipzig, Dept Cardiol & Angiol, Leipzig, Germany
关键词
platelet; fibrinogen receptor antagonist; glycoprotein IIb; conformation; fluorescence resonance energy transfer;
D O I
10.1002/cyto.b.20026
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: Controversial results have been reported concerning the ability of fibrinogen receptor antagonists (fibans) to induce conformational changes in the fibrinogen receptor after binding to it as the initial step of fibrinogen binding and platelet activation. Methods: Platelets in citrated whole blood were stained with several pairs of anti-glycoprotein (anti-GP) IIb-directed monoclonal antibodies conjugated to phycoerythrin (PE) or indirectly labeled with Cy5. Pairs of monoclonal antibodies that induced a high-fluorescence resonance energy transfer (FRET) efficiency served as tools to detect activation-dependent changes of GP IIb after addition of adenosine diphosphate and several fibans. Results: Using the combination of the clones 5B12-PE and P2-biotin/SA-Cy5, a concentration-dependent alteration of the GP IIb conformation was observed after addition of tirofiban, eptifibatide, and lotrafiban. Magnitude and kinetics differed among the investigated substances. Conclusion: The newly developed FRET assay allows the direct investigation of conformational changes of GP IIb after addition of platelet agonists or receptor ligands, as shown for three fibans. (C) 2004 Wiley-Liss, Inc.
引用
收藏
页码:14 / 24
页数:11
相关论文
共 61 条
  • [1] Recent antiplatelet drug trials in the acute coronary syndromes - Clinical interpretation of PRISM, PRISM-PLUS, PARAGON A and PURSUIT
    Alexander, JH
    Harrington, RA
    [J]. DRUGS, 1998, 56 (06) : 965 - 976
  • [2] Effects of glycoprotein IIb/IIIa antagonists on platelet activation: development of a transfer method to mimic peak to trough receptor occupancy
    Billheimer, JT
    He, BK
    Spitz, SM
    Stern, AM
    Seiffert, D
    [J]. THROMBOSIS RESEARCH, 2002, 107 (06) : 303 - 317
  • [3] Serial measurement of surface expressions of CD63, P-selectin and CD40 ligand on platelets in atherosclerotic ischernic stroke - A possible role of CD40 ligand on platelets in atherosclerotic ischemic stroke
    Cha, JK
    Jeong, MH
    Jang, JY
    Bae, HR
    Lim, YJ
    Kim, JS
    Kim, SH
    Kim, JW
    [J]. CEREBROVASCULAR DISEASES, 2003, 16 (04) : 376 - 382
  • [4] Creager M A, 1998, Vasc Med, V3, P257, DOI 10.1177/1358836X9800300314
  • [5] Dery J P, 2002, Minerva Cardioangiol, V50, P531
  • [6] Clinical trials with glycoprotein IIB/IIIA antagonists - No benefit without bleeding?
    Doggrell, SA
    [J]. DRUGS OF TODAY, 2001, 37 (08) : 509 - 531
  • [7] LIGANDS ACTIVATE INTEGRIN ALPHA-IIB-BETA-3 (PLATELET GPIIB-IIIA)
    DU, XP
    PLOW, EF
    FRELINGER, AL
    OTOOLE, TE
    LOFTUS, JC
    GINSBERG, MH
    [J]. CELL, 1991, 65 (03) : 409 - 416
  • [8] Dissociation of glycoprotein IIb/IIIa antagonists from platelets does not result in fibrinogen binding or platelet aggregation
    Frelinger, AL
    Furman, MI
    Krueger, LA
    Barnard, MR
    Michelson, AD
    [J]. CIRCULATION, 2001, 104 (12) : 1374 - 1379
  • [9] FLOW CYTOMETRIC ASSESSMENT OF PLATELET-FUNCTION IN PATIENTS WITH PERIPHERAL ARTERIAL OCCLUSIVE DISEASE
    GALT, SW
    MCDANIEL, MD
    AULT, KA
    MITCHELL, J
    CRONENWETT, JL
    [J]. JOURNAL OF VASCULAR SURGERY, 1991, 14 (06) : 747 - 756
  • [10] Gawaz M, 1999, CIRCULATION, V99, P2